Log in

NASDAQ:TXMD - TherapeuticsMD Stock Price, Forecast & News

$2.06
-0.09 (-4.19 %)
(As of 02/23/2020 02:50 PM ET)
Today's Range
$2.02
Now: $2.06
$2.17
50-Day Range
$2.06
MA: $2.39
$2.81
52-Week Range
$1.82
Now: $2.06
$6.09
Volume4.48 million shs
Average Volume3.34 million shs
Market Capitalization$558.63 million
P/E RatioN/A
Dividend YieldN/A
Beta1.65
TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TXMD
Previous SymbolNYSEMKT:TXMD
CUSIPN/A
Phone561-961-1900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$49.65 million
Book Value$0.41 per share

Profitability

Net Income$-132,620,000.00
Net Margins-354.79%

Miscellaneous

Employees241
Market Cap$558.63 million
Next Earnings Date5/4/2020 (Estimated)
OptionableOptionable

Receive TXMD News and Ratings via Email

Sign-up to receive the latest news and ratings for TXMD and its competitors with MarketBeat's FREE daily newsletter.


TherapeuticsMD (NASDAQ:TXMD) Frequently Asked Questions

What is TherapeuticsMD's stock symbol?

TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."

How were TherapeuticsMD's earnings last quarter?

TherapeuticsMD Inc (NASDAQ:TXMD) issued its quarterly earnings data on Thursday, February, 20th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.20) by $0.01. The business earned $15.90 million during the quarter, compared to analyst estimates of $12.82 million. TherapeuticsMD had a negative net margin of 354.79% and a negative return on equity of 1,047.83%. The firm's quarterly revenue was up 212.4% on a year-over-year basis. During the same quarter last year, the business earned ($0.17) EPS. View TherapeuticsMD's Earnings History.

When is TherapeuticsMD's next earnings date?

TherapeuticsMD is scheduled to release their next quarterly earnings announcement on Monday, May 4th 2020. View Earnings Estimates for TherapeuticsMD.

What guidance has TherapeuticsMD issued on next quarter's earnings?

TherapeuticsMD updated its FY 2020 Pre-Market earnings guidance on Thursday, February, 20th. The company provided EPS guidance of for the period. The company issued revenue guidance of $90-110 million, compared to the consensus revenue estimate of $100.15 million.

What price target have analysts set for TXMD?

9 brokers have issued 12 month price targets for TherapeuticsMD's stock. Their forecasts range from $3.00 to $17.00. On average, they anticipate TherapeuticsMD's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 336.9% from the stock's current price. View Analyst Price Targets for TherapeuticsMD.

What is the consensus analysts' recommendation for TherapeuticsMD?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TherapeuticsMD.

Has TherapeuticsMD been receiving favorable news coverage?

Press coverage about TXMD stock has trended very negative on Sunday, InfoTrie Sentiment reports. The research group ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. TherapeuticsMD earned a coverage optimism score of -3.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for TherapeuticsMD.

Are investors shorting TherapeuticsMD?

TherapeuticsMD saw a increase in short interest in January. As of January 15th, there was short interest totalling 86,820,000 shares, an increase of 9.4% from the December 31st total of 79,360,000 shares. Based on an average daily volume of 3,670,000 shares, the days-to-cover ratio is currently 23.7 days. Currently, 36.6% of the shares of the company are short sold. View TherapeuticsMD's Current Options Chain.

Who are some of TherapeuticsMD's key competitors?

What other stocks do shareholders of TherapeuticsMD own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TherapeuticsMD investors own include Opko Health (OPK), Verastem (VSTM), Teva Pharmaceutical Industries (TEVA), Cleveland-Cliffs (CLF), CannTrust (CNTTF), NVIDIA (NVDA), Horizon Therapeutics (HZNP), Inovio Pharmaceuticals (INO), Global Blood Therapeutics (GBT) and Novavax (NVAX).

Who are TherapeuticsMD's key executives?

TherapeuticsMD's management team includes the folowing people:
  • Mr. Robert G. Finizio, Co-Founder, CEO & Director (Age 48)
  • Mr. John C. K. Milligan IV, Pres, Sec. & Director (Age 57)
  • Dr. Brian A. Bernick, Co-Founder, Chief Clinical Officer & Director (Age 51)
  • Mr. Daniel Alan Cartwright, CFO & Treasurer (Age 61)
  • Mr. Mitchell L. Krassan, Exec. VP & Chief Strategy Officer (Age 53)

Who are TherapeuticsMD's major shareholders?

TherapeuticsMD's stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (6.52%), Bank of New York Mellon Corp (4.84%), Franklin Resources Inc. (3.50%), State Street Corp (2.04%), Bamco Inc. NY (1.41%) and Stifel Financial Corp (1.11%). Company insiders that own TherapeuticsMD stock include Angus C Russell, Brian Bernick, Daniel A Cartwright, Group L P Column, Jane F Barlow, John CK Iv Milligan, Jules A Musing, Robert G Finizio and Tommy G Thompson. View Institutional Ownership Trends for TherapeuticsMD.

Which major investors are selling TherapeuticsMD stock?

TXMD stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Public Employees Retirement Association of Colorado, FMR LLC, Franklin Resources Inc., Sanders Morris Harris LLC, SG Americas Securities LLC, Raymond James & Associates and First Eagle Investment Management LLC. View Insider Buying and Selling for TherapeuticsMD.

Which major investors are buying TherapeuticsMD stock?

TXMD stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Perceptive Advisors LLC, Marshall Wace North America L.P., State Street Corp, Knights of Columbus Asset Advisors LLC, Goldman Sachs Group Inc., Hawk Ridge Capital Management LP and Stifel Financial Corp. Company insiders that have bought TherapeuticsMD stock in the last two years include Angus C Russell, Brian Bernick, Group L P Column, Jane F Barlow, John CK Iv Milligan, Robert G Finizio and Tommy G Thompson. View Insider Buying and Selling for TherapeuticsMD.

How do I buy shares of TherapeuticsMD?

Shares of TXMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is TherapeuticsMD's stock price today?

One share of TXMD stock can currently be purchased for approximately $2.06.

How big of a company is TherapeuticsMD?

TherapeuticsMD has a market capitalization of $558.63 million and generates $49.65 million in revenue each year. The company earns $-132,620,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis. TherapeuticsMD employs 241 workers across the globe.View Additional Information About TherapeuticsMD.

What is TherapeuticsMD's official website?

The official website for TherapeuticsMD is http://www.therapeuticsmd.com/.

How can I contact TherapeuticsMD?

TherapeuticsMD's mailing address is 951 Yamato Road Suite 220, BOCA RATON FL, 33431. The company can be reached via phone at 561-961-1900 or via email at [email protected]


MarketBeat Community Rating for TherapeuticsMD (NASDAQ TXMD)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  345 (Vote Outperform)
Underperform Votes:  301 (Vote Underperform)
Total Votes:  646
MarketBeat's community ratings are surveys of what our community members think about TherapeuticsMD and other stocks. Vote "Outperform" if you believe TXMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TXMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel